Stop Antiplatelet
PreclinicalSmall molecule
Stop Antiplatelet is one of 3 small molecule programs targeting Antiplatelet Therapy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Antiplatelet Therapy
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Kengreal
Chiesi Farmaceutici S.p.A.Approved
Stop Antiplatelet
UUlsan University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stop Antiplatelet. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUlsan University Hospital